The trial will enrol approximately 650 ovarian cancer patients across Asia, Europe, North America, and South America. Credit: Chinnapong / Shutterstock.

Daiichi Sankyo and Merck (MSD) have dosed the first subject in the global Phase II/III REJOICE-Ovarian01 clinical trial of raludotatug deruxtecan (R-DXd) in platinum-resistant, ovarian cancer patients.

Discovered by Daiichi Sankyo and being co-developed by the companies, R-DXd is an investigational antibody-drug conjugate (ADC) targeting human cadherin-6 (CDH6).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multicentre, randomised, open-label trial will assess the efficacy and safety of the ADC in approximately 650 subjects across Europe, Asia, North America, and South America.

Participants will include those with primary peritoneal or fallopian tube cancer, having received one to three systemic anticancer therapies previously.

In the Phase II segment of the trial, the tolerability and safety of three doses of R-DXd will be analysed to detect the recommended dose.

The primary endpoint of this portion of the trial is the objective response rate (ORR), while secondary endpoints include the investigator’s ORR, duration of response, progression-free survival (PFS), and disease control rate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The subsequent Phase III part will compare the efficacy and safety of the chosen R-DXd dose against the investigator’s choice of chemotherapy.

ORR and PFS will be the trial’s dual primary endpoints.

The trial’s initiation follows data from an ongoing Phase I study of R-DXd.

Daiichi Sankyo oncology clinical development global head Mark Rutstein said: “Raludotatug deruxtecan has shown promising activity in a Phase I trial of patients with advanced ovarian cancer.

“The REJOICE-Ovarian01 trial, which is our first trial initiation for raludotatug deruxtecan in collaboration with Merck, will evaluate the efficacy of this CDH6 directed DXd antibody-drug conjugate versus investigator’s choice of chemotherapy in patients with platinum-resistant ovarian cancer.”

Prior to this development, the US Food and Drug Administration has accepted AstraZeneca and Daiichi Sankyo‘s biologics licence application for datopotamab deruxtecan for treating a subset of breast cancer patients.